Fig. 3

Exosomal MALAT1 sponged miR-26a/26b to increase FUT4 expression in primary CRC cells. a The expression of miR-26a and miR-26b was determined in SW480 cells treated with Exo-SW620. b The expression of miR-26a and miR-26b in HCT-8 cells was shown after treatment with Exo-LoVo. c The proliferative activity was measured by colony formation assay in SW480 cells treated with miR-26a/26b mimic in presence of Exo-SW620. d Wound healing and transwell assays were used to determine the migratory and invasive abilities of SW480 cells with different treatment. e CCK8 assay was carried out to measure the viability of treated SW480 cells. f FUT4 expression was determined in SW480 cells treated with miR-26a/26b mimic in presence of Exo-SW620. g Microarray analysis for six possible target lncRNAs of miR-26a and miR-26b in SW620 and SW480 cells. h Relative MALAT1 expression was determined by qRT-PCR in CRC cells. i MALAT1 levels were analyzed in SW480 and HCT-8 cells incubated with Exo-SW620 or Exo-LoVo for 24 h with or without DRB (15 mM). j Sequence alignment of miR-26a and miR-26b with the binding sites in the wild-type and mutant-type regions of MALAT1 was shown. k The relative luciferase activity of 293 T cells was tested after co-transfection with MALAT1 wide-type and miR-26a mimic or miR-26b mimic. l RIP assay was performed, and the co-precipitated RNA was subjected to qRT-PCR. RNA levels were presented as fold enrichment in Ago2 relative to IgG immunoprecipitates. Data were the means ± SD of triplicate determinants (*P < 0.05, **P < 0.01)